SMT C1100 - A Phase 1, Open-label, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Paediatric Patients with Duchenne Muscular Dystrophy
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Ezutromid (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Summit plc
- 30 Sep 2015 Results published in Summit Therapeutics media release.
- 03 Jul 2014 Results published in the Media Release.
- 03 Jul 2014 According to a Summit plc media release, top-line results were reported in May 2014.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History